View Older Stories View More Recent Stories

Nov 29, 2021 06:30AM HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic
Nov 17, 2021 06:00AM Chroma Medicine Launches with $125M in Financing to Deliver on the Promise of Epigenetic Editing
Nov 5, 2021 04:43PM Form SC 13G Xilio Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Nov 5, 2021 04:38PM Form SC 13D Aerovate Therapeutics, Filed by: Atlas Venture Associates XII, LLC
Nov 4, 2021 10:56AM Form 13F-NT ATLAS VENTURE FUND VI For: Sep 30
Nov 4, 2021 10:55AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 4, 2021 10:53AM Form 13F-HR Atlas Venture Advisors, For: Sep 30
Nov 4, 2021 10:52AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 4, 2021 10:51AM Form 13F-HR Atlas Venture Associates For: Sep 30
Oct 26, 2021 05:02PM Form 4 Xilio Therapeutics, Inc. For: Oct 26 Filed by: Atlas Venture Fund XI, L.P.
Oct 21, 2021 08:49PM Form 3 Xilio Therapeutics, Inc. For: Oct 21 Filed by: Atlas Venture Fund XI, L.P.
Oct 14, 2021 06:30AM Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund
Oct 1, 2021 01:07PM Form D Atlas Venture Opportunit
Oct 1, 2021 07:00AM Atlas Venture Announces $300 Million Second Opportunity Fund
Sep 29, 2021 07:16PM Form 4 Generation Bio Co. For: Sep 27 Filed by: Atlas Venture Associates Opportunity I, LLC
Sep 28, 2021 08:15AM Nucleate launches nationwide to empower the next generation of biotech leaders
Sep 24, 2021 09:00PM Form 4 Generation Bio Co. For: Sep 22 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Sep 22, 2021 06:59AM Endpoints News names the 11 most promising biotech startups of 2021
Sep 21, 2021 04:40PM Form 4 Generation Bio Co. For: Sep 17 Filed by: Atlas Venture Fund X, L.P.
Sep 15, 2021 10:00AM Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients
Sep 9, 2021 08:00AM Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Sep 2, 2021 06:00AM Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
Aug 31, 2021 07:00AM Versanis Bio Announces $70 Million Series A Financing to Advance Bimagrumab for the Treatment of Obesity
Aug 18, 2021 07:00AM Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases
Aug 17, 2021 08:30AM Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer
Aug 12, 2021 10:42AM Form 4 Kymera Therapeutics, For: Aug 11 Filed by: Atlas Venture Associates X, LLC
Aug 11, 2021 11:42AM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 11, 2021 11:42AM Form 13F-NT ATLAS VENTURE FUND VI For: Jun 30
Aug 11, 2021 11:38AM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 11, 2021 11:38AM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Aug 11, 2021 11:38AM Form 13F-HR Atlas Venture Associates For: Jun 30
Jul 15, 2021 04:34PM Form 4 Dyne Therapeutics, Inc. For: Jul 13 Filed by: Atlas Venture Fund XI, L.P.
Jul 13, 2021 06:00AM Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs
Jul 12, 2021 07:00AM Atlas Venture Welcomes Jodie Morrison as Venture Partner
Jul 8, 2021 07:30AM Life Edit Therapeutics Announces Newly Established Scientific Advisory Board
Jul 6, 2021 04:27PM Form 4 Aerovate Therapeutics, For: Jul 02 Filed by: Atlas Venture Associates XII, L.P.
Jun 29, 2021 08:47PM Form 3 Aerovate Therapeutics, For: Jun 29 Filed by: Atlas Venture Fund XII, L.P.
Jun 29, 2021 08:10PM Form 3 INTEGRAL AD SCIENCE HOLD For: Jun 29 Filed by: Atlas Venture Associates VIII, Inc.
Jun 28, 2021 04:57PM Form 4 Generation Bio Co. For: Jun 24 Filed by: Atlas Venture Associates Opportunity I, LLC
Jun 23, 2021 08:27PM Form 4 Generation Bio Co. For: Jun 21 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Jun 22, 2021 07:00AM Vedere Bio II Announces Appointment of Gabor Veres, Ph.D., as Chief Scientific Officer
Jun 21, 2021 04:51PM Form 4 Generation Bio Co. For: Jun 16 Filed by: Atlas Venture Fund X, L.P.
Jun 17, 2021 04:16PM TCW Special Purpose Acquisition Corp. (TSPQ) Appoints David W. Rye to its Board
Jun 17, 2021 04:15PM TCW Special Purpose Acquisition Corp. Appoints David W. Rye to Board of Directors
Jun 2, 2021 06:41PM Form 4 Day One Biopharmaceutica For: Feb 01 Filed by: Atlas Venture Associates XI, LLC
Jun 2, 2021 09:00AM Harvard Business School Announces Its 2021-2022 Blavatnik Fellows
May 26, 2021 09:56PM Form 3 Day One Biopharmaceutica For: May 26 Filed by: Atlas Venture Fund XI, L.P.
May 18, 2021 06:17PM Form 4 Kymera Therapeutics, For: May 18 Filed by: Atlas Venture Fund X, L.P.
May 18, 2021 07:00AM Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
May 14, 2021 10:39AM Form 13F-HR Atlas Venture Advisors, For: Mar 31
View More Recent Stories View Older Stories